Objective To investigate the clinical features of type 1 autoimmune pancreatitis ( AIP) , and to deepen the understanding of this disease, reduce false positive rate, and enhance people' s awareness of this disease. Methods A retrospective analysis was performed for the clinical data of 13 patients with type 1 AIP who were admitted to The First Hospital of Jilin University from January 2012 to December 2016, including general status, clinical manifestations, laboratory serological examination, imaging findings, histopathological findings, treatment, and prognosis. Results Of all 13 patients, there were 9 male and 4 female patients with a mean age of 60. 08 ± 9. 47 years. Major clinical manifestations included jaundice ( 69. 2%) , abdominal pain ( 61. 5%) , and weight loss ( 61. 5%) . The most common organ involved was bile duct ( 46. 2%) , and 30. 8% of the patients had sclerosing cholangitis. Of all patients, 23. 1% had diabetes. As for serological markers, 92. 30% patients had more than 2 times increase in Ig G4, and 7. 69% had 1-2 times increase in Ig G4; 53. 85% patients had an increase in CA19-9; 69. 23% patients had an increase in total bilirubin; more than two thirds of the patients had an increase in aminotransferases or gamma-glutamyl transpeptidase. As for imaging findings, 53. 8% patients had diffuse enlargement of the pancreas on CT, 46. 2% had focal enlargement of the pancreas, and 46. 2% patients had low-density cyst-like shadow in pancreatic lesions. Pathological examination showed fibrous connective tissue proliferation with infiltration of lymphocytes and plasma cells. All patients were given standard glucocorticoid therapy ( initial dose of prednisone: 30-40 mg/d) and the remission rate of glucocorticoid therapy was 100%. The follow-up time was 12 months, and one patient experienced multiple recurrences in the course of the disease. Conclusion Type 1 AIP is the local manifestation of Ig G4-associated disease in the pancreas, which often occurs in middle-aged and elderly men, and most patients are complicated by extrapancreatic lesions. Glucocorticoid therapy is effective and most patients have good prognosis. Recurrence often occurs in the case of no standard or long-term glucocorticoid therapy.
[1]FINKELBERG DL, SAHANI D, DESHPANDE V, et al.Autoimmune pancreatitis[J].N Engl J Med, 2006, 355 (25) :2670-2676.
|
[2]SUGUMAR A, CHARI ST.Diagnosis and treatment of autoimmune pancreatitis[J].Curr Opin Gastroenterol, 2010, 26 (5) :513-518.
|
[3]SHIMOSEGAWA T, CHARI ST, FRULLONI L, et al.International consensus diagnostic criteria for autoim-munepancreatitis:guidelines of the International Association of Pancreatology[J].Pancreas, 2011, 40 (3) :352-358.
|
[4]WU LL, LI W.An analysis of clinical characteristics of autoimmune pancreatitis[J].Chin J Intern Med, 2010, 49 (11) :943-946. (in Chinese) 吴丽丽, 李闻.自身免疫性胰腺炎临床特征分析[J].中华内科杂志, 2010, 49 (11) :943-946.
|
[5]KAMISAWA T, CHAFF ST, GIDAY SA, et al.Clinical profile of autoimmune pancreatitis and its histological subtypes:An international multieenter survey[J].Pancreas, 2011, 40 (6) :809-814.
|
[6] LI ZS.Consensus on autoimmune pancreatitis in China (2012 Draft, Shanghai) [J].Chin J Pancreatol, 2012, 12 (6) :410-418. (in Chinese) .李兆申.我国自身免疫性胰腺炎共识意见 (草案2012, 上海) [J].中华胰腺病杂志, 2012, 12 (6) :410-418。
|
[7]CULVER EL, BATEMAN AC.Ig G4-related disease:can non-classical histopathological features orthe examination of clinically uninvolved tissues be helpful in the diagnosis?[J].J Clin Pathol, 2012, 65:963-969.
|
[8]HUANG Q, ZOU XP.The diagnosis of IGG4-associated autoimmune pancreatitis[J].Chin J Digestive Endoscopy, 2013, 30 (6) :301-303. (in Chinese) .黄勤, 邹小平.Ig G4相关的自身免疫性胰腺炎的诊断[J].中华消化内镜杂志, 2013, 30 (6) :301-303.
|
[9]CARBOGNIN G, GIRARDI V, BIASIUTTI C, et al.Autoimmune pancreatitis:imaging findings on contrast-enhanced MR, CT and dynamic secretin——enhanced MRCP[J].Radial Med, 2009, 114 (8) :1214-1231.
|
[10]ASBUN HJ, CONLON K, FERNANDEZ-CRUZ L, et al.When to perform a pancreatoduodenectomy in the absence of positive histology?A consensus statement by the Intemational Study Group of Pancreatics Surgery[J].Surgery, 2014, 155 (5) :887-892.
|
[11]SUN GF, ZUO CJ, SHAO CW, et al.Focal autoimmune pancreatitis:ra-diological characteristics help to distinguish from pancreatic cancer[J].World J Gastroenterol, 2013, 19 (23) :3634-3641.
|
[12]KAZAKI K, UCHIDA K.Autoimmune panereatitis:the past, present, and future[J].Pancreas, 2015, 44 (7) :1006-1016.
|
[13]KAMISAWA T, TAKUMA K, HARA S, et al.Management strategies for autoimmune pancreatitis[J].Expert Opin Pharmacother, 2011, 12 (14) :2149-2159.
|
[14]ZHAO XD, MA YS, YANG YM.International consensus for the treatment of autoimmune pancreatitis (2016) [J].J Clin Hepatol, 2017, 33 (4) :623-626, (in Chinese) .赵旭东, 马永蔌, 杨尹默.2016年国际胰腺病协会共识:自身免疫性胰腺炎的治疗[J].临床肝胆病杂志, 2017, 33 (4) :623-627.
|
[15]HART PA, ZEN Y, CHARI ST.Recent ADVANCES IN AUTOIMMUNE PANCREATITIs[J].Gastroenterology, 2015, 149 (1) :39-51.
|